The FDA has approved the Abbott RealTime HCV Genotype II test, which can help doctors guide treatment by differentiating genotypes 1, 1a, 1b, 2, 3, 4 and 5 of the hepatitis C virus. The new test is intended for use in patients known to have the infection and not as a diagnostic test or a screening tool for blood, according to the FDA.

Related Summaries